{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:08:40Z","timestamp":1774282120829,"version":"3.50.1"},"reference-count":31,"publisher":"Akademiai Kiado Zrt.","issue":"12","license":[{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2026,3,22]]},"abstract":"Az autoimmun betegs\u00e9gek indik\u00e1ci\u00f3s k\u00f6r\u00e9ben bevezetett adalimumab-metotrex\u00e1t\n kett\u0151s ter\u00e1pia mell\u00e9 adott \u00e1thidal\u00f3 szteroidter\u00e1pia jelent\u0151sen hozz\u00e1j\u00e1rul a\n t\u00fcd\u0151gyullad\u00e1s kock\u00e1zat\u00e1nak fokoz\u00f3d\u00e1s\u00e1hoz. A szerz\u0151k a nemzetk\u00f6zi irodalmat\n \u00e1ttekintve, k\u00f3rk\u00e9penk\u00e9nt \u00e9rt\u00e9kelik az adalimumab-monoter\u00e1pia, az\n adalimumab-metotrex\u00e1t kett\u0151s \u00e9s az adalimumab-metotrex\u00e1t-szteroid h\u00e1rmas\n kombin\u00e1ci\u00f3 okozta t\u00fcd\u0151gyullad\u00e1s incidenci\u00e1j\u00e1t, valamint a szteroidle\u00e9p\u00edt\u0151\n protokollokat. Kit\u00e9rnek az adalimumab k\u00f3rk\u00e9penk\u00e9nt javasolt, hat\u00e9kony\n szintjeinek \u00e9s az antiadalimumab-antitest m\u00e9r\u00e9s\u00e9nek fontoss\u00e1g\u00e1ra, mely az\n autoimmun betegs\u00e9gek prec\u00edzi\u00f3s medicin\u00e1j\u00e1nak r\u00e9sze. Ezek a laborvizsg\u00e1latok\n seg\u00edtenek azonos\u00edtani a szteroidf\u00fcgg\u0151s\u00e9g okait, \u00e9s ir\u00e1nyt mutatnak a tov\u00e1bbi\n szteroidmentes \u00e1llapot el\u00e9r\u00e9s\u00e9hez, amelyen kereszt\u00fcl a kezelt betegek\n t\u00fcd\u0151gyullad\u00e1s\u00e1nak kock\u00e1zata cs\u00f6kkenthet\u0151. Orv Hetil. 2026; 167(12): 466\u2013475.<\/jats:p>","DOI":"10.1556\/650.2026.33510","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:39:59Z","timestamp":1774280399000},"page":"466-475","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["A t\u00fcd\u0151gyullad\u00e1s kock\u00e1zata adalimumabkezel\u00e9s alatt"],"prefix":"10.1556","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8443-6176","authenticated-orcid":true,"given":"Gy\u00f6rgy","family":"Bernscherer","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Csal\u00e1dorvosi Tansz\u00e9k Budapest Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csaba","family":"Karab\u00e9lyos","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Genetikai, Sejt- \u00e9s Immunbiol\u00f3giai Int\u00e9zet Budapest Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1gnes","family":"Kov\u00e1csn\u00e9 dr. T\u00f3th","sequence":"additional","affiliation":[{"name":"Sz\u00e9chenyi Istv\u00e1n Egyetem, Eg\u00e9szs\u00e9g- \u00e9s Sporttudom\u00e1nyi Kar Gy\u0151r Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"#cr-split#-R1.1","doi-asserted-by":"crossref","unstructured":"Zhao M, Zhai H, Li H, et al. Age-standardized incidence, prevalence, and mortality rates of autoimmune diseases in adolescents and young adults (15-39 years): an analysis based on the global burden of disease study 2021. BMC Public Health 2024","DOI":"10.1186\/s12889-024-19290-3"},{"key":"#cr-split#-R1.2","doi-asserted-by":"crossref","unstructured":"24: 1800. https:\/\/doi.org\/10.1186\/s12889-024-19290-3","DOI":"10.1186\/s12889-024-19290-3"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Ma Y, Chen H, Lv W, et al. Global, regional and national burden of\n rheumatoid arthritis from 1990 to 2021, with projections of incidence to 2050: a\n systematic and comprehensive analysis of the Global Burden of Disease study\n 2021. Biomark Res. 2025; 13: 47.\n https:\/\/doi.org\/10.1186\/s40364-025-00760-8","DOI":"10.1186\/s40364-025-00760-8"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Chen X, Xiang X, Xia W, et al. Evolving trends and burden of\n inflammatory bowel disease in Asia, 1990-2019: a comprehensive analysis based on\n the global burden of disease study. J Epidemiol Glob Health 2023; 13: 725-739.\n https:\/\/doi.org\/10.1007\/s44197-023-00145-w","DOI":"10.1007\/s44197-023-00145-w"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"S\u00fdkora J, Pomaha\u010dov\u00e1 R, Kreslov\u00e1 M, et al. Current global trends in\n the incidence of pediatric-onset inflammatory bowel disease. World J\n Gastroenterol. 2018; 24: 2741-2763.\n https:\/\/doi.org\/10.3748\/wjg.v24.i25.2741","DOI":"10.3748\/wjg.v24.i25.2741"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Juszt J, Benedek N, Mohay G, et al. A rare condition underlying\n childhood back pain: chronic nonbacterial osteomyelitis. [A gyermekkori\n h\u00e1tf\u00e1jdalom h\u00e1tter\u00e9ben \u00e1ll\u00f3 ritka k\u00f3rk\u00e9p: kr\u00f3nikus nem bakteri\u00e1lis\n osteomyelitis.] Orv Hetil. 2024; 165: 595-600. [Hungarian]\n https:\/\/doi.org\/10.1556\/650.2024.33021","DOI":"10.1556\/650.2024.33021"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of\n anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;\n 9: 164-172. https:\/\/doi.org\/10.1038\/nrrheum.2013.4","DOI":"10.1038\/nrrheum.2013.4"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Garc\u00eas S, Demengeot J, Benito-Garcia E. The immunogenicity of\n anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review\n of the literature with a meta-analysis. Ann Rheum Dis. 2013; 72: 1947-1955.\n https:\/\/doi.org\/10.1136\/annrheumdis-2012-202220","DOI":"10.1136\/annrheumdis-2012-202220"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Ungar B, Chowers Y, Yavzori M, et al. The temporal volution of\n antidrug antibodies in patients with inflammatory bowel disease treated with\n infliximab. Gut 2014; 63: 1258-1264.\n https:\/\/doi.org\/10.1136\/gutjnl-2013-305259","DOI":"10.1136\/gutjnl-2013-305259"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Fragoulis GE, Nikiphorou E, Dey M, et al. 2022 EULAR recommendations\n for screening and prophylaxis of chronic and opportunistic infections in adults\n with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2023; 82:\n 742-753. https:\/\/doi.org\/10.1136\/ard-2022-223335","DOI":"10.1136\/ard-2022-223335"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Kucharzik T, Ellul P, Greuter T, et al. ECCE guidelines on the\n prevention, diagnosis and management of infections in inflammatory bowel\n disease. J Crohns Colitis 2021; 15: 879-913. Erratum: J Crohns Colitis. 2023;\n 17: 149. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab052","DOI":"10.1093\/ecco-jcc\/jjab052"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Di Franco M, Lucchino B, Spaziante M, et al. Lung infections in\n systemic rheumatic disease: focus on opportunistic infections. Int J Mol Sci.\n 2017; 18: 293. https:\/\/doi.org\/10.3390\/ijms18020293","DOI":"10.3390\/ijms18020293"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Long MD, Martin C, Sandler RS, et al. Increased risk of pneumonia\n among patients with inflammatory bowel disease. Am J Gastroenterol. 2013; 108:\n 240-248. https:\/\/doi.org\/10.1038\/ajg.2012.406","DOI":"10.1038\/ajg.2012.406"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and\n the risk of hospitalization for pneumonia: associations with prednisone,\n disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.\n Arthritis Rheum. 2006; 54: 628-634.\n https:\/\/doi.org\/10.1002\/art.21568","DOI":"10.1002\/art.21568"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Kao LT, Lee CZ, Liu SP, et al. Psoriasis and the risk of pneumonia:\n a population-based study. PLOS ONE 2014; 9: e116077.\n https:\/\/doi.org\/10.1371\/journal.pone.0116077","DOI":"10.1371\/journal.pone.0116077"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Vassilopoulos A, Thomas K, Vassilopoulos D. Infections in psoriatic\n arthritis: association with treatment. Ther Adv Musculoskelet Dis. 2024; 16:\n 1759720X241289201.\n https:\/\/doi.org\/10.1177\/1759720X241289201","DOI":"10.1177\/1759720X241289201"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Chung HY, Tam LS, Chan SCW, et al. Hong Kong Society of\n Rheumatology. Risk of community-acquired pneumonia requiring hospitalization in\n patients with spondyloarthritis. Ther Adv Musculoskelet Dis. 2020; 12:\n 1759720X20962618.\n https:\/\/doi.org\/10.1177\/1759720X20962618","DOI":"10.1177\/1759720X20962618"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Boers M. Viewpoint: Glucocorticoids in the treatment of rheumatoid\n arthritis: points to (re)consider. Rheumatology (Oxford) 2023; 62: 3534-3537.\n https:\/\/doi.org\/10.1093\/rheumatology\/kead309","DOI":"10.1093\/rheumatology\/kead309"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of\n antidrug antibodies against adalimumab and association with disease activity and\n treatment failure during long-term follow-up. JAMA 2011; 305: 1460-1468.\n https:\/\/doi.org\/10.1001\/jama.2011.406","DOI":"10.1001\/jama.2011.406"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Jyssum I, Gehin JE, Sexton J, et al. Adalimumab serum levels and\n anti-drug antibodies: associations to treatment response and drug survival in\n inflammatory joint diseases. Rheumatology (Oxford) 2024; 63: 1746-1755.\n https:\/\/doi.org\/10.1093\/rheumatology\/kead525","DOI":"10.1093\/rheumatology\/kead525"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Blackwell J, Selinger C, Raine T, et al. Steroid use and misuse: a\n key performance indicator in the management of IBD. Frontline Gastroenterol.\n 2020; 12: 207-213.\n https:\/\/doi.org\/10.1136\/flgastro-2019-101288","DOI":"10.1136\/flgastro-2019-101288"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Orlando A, Renna S, Mocciaro F, et al. Adalimumab in\n steroid-dependent Crohn\u2019s disease patients: prognostic factors for clinical\n benefit. Inflamm Bowel Dis. 2012; 18: 826-831.\n https:\/\/doi.org\/10.1002\/ibd.21835","DOI":"10.1002\/ibd.21835"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Ritter E, Hirsch A, Isakov NF, et al. Higher maintenance adalimumab\n trough levels are associated with achievement of advanced remission targets in\n patients with inflammatory bowel disease. J Clin Gastroenterol. 2021; 55:\n 810-814.\n https:\/\/doi.org\/10.1097\/MCG.0000000000001435","DOI":"10.1097\/MCG.0000000000001435"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Mrowietz U, Domm S. Systemic steroids in the treatment of psoriasis:\n what is fact, what is fiction? J Eur Acad Dermatol Venereol. 2013; 27:\n 1022-1025.\n https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04656.x","DOI":"10.1111\/j.1468-3083.2012.04656.x"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Meyer MW, Zachariae C, Bendtzen K, et al. Lack of anti-drug\n antibodies in patients with psoriasis well-controlled on long-term treatment\n with tumour necrosis factor inhibitors. Acta Derm Venereol. 2012; 92: 362-364.\n https:\/\/doi.org\/10.2340\/00015555-1376","DOI":"10.2340\/00015555-1376"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Vincken NL, Balak DM, Knulst AC, et al. Systemic glucocorticoid use\n and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic\n review. Rheumatology (Oxford) 2022; 61: 4232-4244.\n https:\/\/doi.org\/10.1093\/rheumatology\/keac129","DOI":"10.1093\/rheumatology\/keac129"},{"key":"R26","unstructured":"Kataria RK, Brent LH. Spondyloarthropathies. Am Fam Physician 2004;\n 69: 2853-2860."},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Papamichael K, Cheifetz AS. Is it prime time for proactive\n therapeutic drug monitoring of anti-tumor necrosis factor therapy in\n inflammatory bowel disease? Gastroenterology 2019; 157: 922-924.\n https:\/\/doi.org\/10.1053\/j.gastro.2019.08.001","DOI":"10.1053\/j.gastro.2019.08.001"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Jaffe GJ, Dick AD, Br\u00e9zin AP, et al. Adalimumab in patients with\n active noninfectious uveitis. N Engl J Med. 2016; 375: 932-943.\n https:\/\/doi.org\/10.1056\/NEJMoa1509852","DOI":"10.1056\/NEJMoa1509852"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of\n adalimumab for hidradenitis suppurativa. N Engl J Med. 2016; 375: 422-434.\n https:\/\/doi.org\/10.1056\/NEJMoa1504370","DOI":"10.1056\/NEJMoa1504370"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Kov\u00e1cs K, Nagyp\u00e1l P, V\u00e1s\u00e1rhelyi B, et al. Frequency of antibody\n formation during biological therapies in inflammatory bowel diseases.\n Illustrated by original data. [Az antitestk\u00e9pz\u0151d\u00e9s gyakoris\u00e1ga biol\u00f3giai\n ter\u00e1pi\u00e1k sor\u00e1n gyullad\u00e1sos b\u00e9lbetegs\u00e9gekben. Saj\u00e1t adatokkal illusztr\u00e1lva.] Orv\n Hetil. 2026; 167: 291-299. [Hungarian]\n https:\/\/doi.org\/10.1556\/650.2026.33493","DOI":"10.1556\/650.2026.33493"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/167\/12\/article-p466.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/167\/12\/article-p466.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/167\/12\/article-p466.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:40:07Z","timestamp":1774280407000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/167\/12\/article-p466.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,22]]},"references-count":31,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.1556\/650.2026.33510","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,22]]}}}